Cardiol Therapeutics Inc Class A is facing a downturn as market pressures mount.
Cardiol Therapeutics Inc Class A (CRDL.TO) is seeing a decline in its stock price, down 2.96% in today’s trading session. This drop comes as investors remain cautious in a broader market landscape.
Investor takeaway: Investors should stay alert as Cardiol Therapeutics navigates challenges that could affect its future performance, especially considering its recent financing activities.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$304.91M
52W high
$2.70
52W low
$1.23
1W change
+27.36%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 122.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+122.2% Upside
Current Price
C$2.70
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
68.2%
Annualized
90-Day Vol
58.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.23
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.87 | C$2.27 – C$3.63 |
| 60 trading days | C$3.04 | C$2.18 – C$4.24 |
| 90 trading days | C$3.23 | C$2.15 – C$4.85 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Cardiol Therapeutics' market cap now sits at CA$304.91 million.
With a current stock price of CA$2.62, the company’s market cap reflects uncertainty among investors in this tough trading environment.
Bull case
Despite today’s decline, Cardiol Therapeutics has a promising pipeline and has successfully raised capital to support its ongoing clinical trials. This could set the stage for future growth.
Bear case
The recent drop in stock price raises concerns about investor confidence, particularly since there hasn’t been significant news to support the stock, along with the company’s ongoing financial challenges.
Advertisement
Market Performance Overview
Cardiol Therapeutics Inc Class A has seen its stock price decrease by 2.96% in today’s trading session, closing at CA$2.62. This decline reflects the tough environment the company is facing, especially as it deals with its financial situation and ongoing clinical trials.
Investor Sentiment and Future Outlook
The recent downturn in Cardiol's stock price may suggest waning investor confidence. While the company has secured funding through its recent financing efforts, the lack of significant news or developments raises questions about its short-term direction. Investors should consider these factors carefully when evaluating their positions in CRDL.TO.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
